Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer

Hajjar, A.
Ergun, M.A.
Alagoz, O.
Rampurwala, M.

Open PDF

Open link

Publication date

June 2019

DOI

10.1371/journal.pone.0217778

Publisher

Public Library of Science (PLoS)

Journal

PLoS ONE

Abstract

Adjuvant paclitaxel and trastuzumab has been shown to be an effective regimen with low risk of cancer recurrence and treatment-related toxicities in early-stage node-negative, HER2-positive breast cancer. We investigated the cost-effectiveness of this regimen

Extracted data

We use cookies to provide a better user experience.

Data Protection

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer

Abstract

Extracted data

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer

Abstract

Extracted data

Related items

Related items